Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495764 · ClinicalTrials.gov registry record
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
A clinical trial, sponsored by Davita Clinical Research.
- Completed
- Registry status
- 2,315
- Enrollment target
NCT04495764: Completed study, sponsored by Davita Clinical Research.
NCT04495764 is a clinical trial that has completed, run by Davita Clinical Research. The registered enrollment target is 2,315 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04495764 has completed, sponsored by Davita Clinical Research.
- COMPLETED
- Registry status
- 2,315 participants
- Enrollment target
Study Summary
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,315 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2021-02-12 |
What the finished NCT04495764 record still lists
NCT04495764 is an observational study that tracks outcomes without assigning an intervention. Its 2,315 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04495764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04495764 about?
NCT04495764 is a clinical study titled "Registry of Sustained Immunity to COVID-19 Among ESKD Patients". This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection...
What is the current status of trial NCT04495764?
This trial is currently completed. The enrollment target is 2,315 participants. The study started on 2020-07-20. Estimated completion is 2021-02-12.
Who is sponsoring clinical trial NCT04495764?
This trial is sponsored by Davita Clinical Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI